Stories of mis-diagnoses in the media

I see no justification for dragging it through public media. What point is being made? If the point is that North American healthcare is very poor value for money, then we all know that. Maybe the answer is to vote differently next time!!!
Lol ok.. the celebrity podcast and life story is an important artifact of pop culture Jonathan.. that is why!
 
The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative (2016)

Over the past few years, MRI has become an indispensable tool for diagnosing multiple sclerosis (MS). However, the current MRI criteria for MS diagnosis have imperfect sensitivity and specificity.

The central vein sign (CVS) has recently been proposed as a novel MRI biomarker to improve the accuracy and speed of MS diagnosis. Evidence indicates that the presence of the CVS in individual lesions can accurately differentiate MS from other diseases that mimic this condition. However, the predictive value of the CVS for the development of clinical MS in patients with suspected demyelinating disease is still unknown. Moreover, the lack of standardization for the definition and imaging of the CVS currently limits its clinical implementation and validation.

On the basis of a thorough review of the existing literature on the CVS and the consensus opinion of the members of the North American Imaging in Multiple Sclerosis (NAIMS) Cooperative, this article provides statements and recommendations aimed at helping radiologists and neurologists to better understand, refine, standardize and evaluate the CVS in the diagnosis of MS.

Web | PDF | Nature Reviews Neurology | Open Access

Accuracy of the central vein sign in diagnosis of multiple sclerosis: a systematic review and meta-analysis (2026)

BACKGROUND
The central vein sign (CVS) is a promising imaging marker of multiple sclerosis (MS). We performed a systematic review and meta-analysis to evaluate the diagnostic accuracy of CVS-based rules in the differential diagnosis of MS and to identify the best cutoffs for these rules.

METHODS
PubMed, Embase, and Scopus were systematically searched for available evidence. Data extracted were entered into Bayesian models recommended by the Cochrane network. Summary sensitivity and specificity of CVS-based diagnostic rules across different positivity thresholds were calculated. A meta-regression for the role of gadolinium-based MRI protocols was also performed.

RESULTS
3434 patients from 28 studies were included. Three CVS-based diagnostic rules were found: the first one considers the percentage of CVS + lesions (relative threshold method), the second one the presence of CVS in a given number of lesions selected in T2 sequences (select-n method), and the third one the presence of a given number of CVS + lesions in gradient-echo sequences (select-n* method). For relative threshold method, the best cutoff was 37.5% (sensitivity 97.3%, 95%CI 90.9–99.6%; specificity 90.4%, 95%CI 83.2–95.9%; Youden index 0.877); for select-n* method, 4 was the best threshold (sensitivity 87.1%, 95%CI 66.9–96.6%; specificity 88.2%, 95%CI 65.1–98.1%; Youden index 0.753). Use of gadolinium-based MRI protocols was irrelevant (for relative threshold method RDOR = 6.62, 95%CI 0.68–71.27; for select-n* method RDOR = 2.52, 95%CI 0.35–15.36).

CONCLUSIONS
Relative threshold and select-n* methods are good predictors of MS diagnosis. This synthesis should support the use of CVS in clinical practice and prompt further research.

Web | PDF | Journal of Neurology | Paywall

Diagnostic performance of central vein sign and paramagnetic rim lesion integration for multiple sclerosis (2026)

BACKGROUND
The central vein sign (CVS) and the paramagnetic rim lesion (PRL) are neuroimaging biomarkers of multiple sclerosis (MS).

OBJECTIVES
To determine the diagnostic performance of CVS and PRL integration in people presenting for initial diagnostic evaluation of MS.

METHODS
Adults with clinical/radiological suspicion of MS, aged 18–65, with CVS and PRL assessment from the CentrAl Vein Sign in MS (CAVS-MS) pilot were included. Diagnostic performance of CVS and PRL combinations was evaluated, with 2017 McDonald criteria as the reference standard.

RESULTS
Seventy-eight participants were included (71% female, 86% white, 37 with MS). The combination of ⩾1 CVS and ⩾1 PRL demonstrated sensitivity/specificity of 0.76 (95% CI, 0.59, 0.88) and 0.93 (95% CI, 0.80, 0.98). The combination of ⩾6 CVS and ⩾1 PRL demonstrated sensitivity/specificity of 0.57 (95% CI, 0.39, 0.73) and 1.00 (95% CI, 0.91, 1.00). In those with cerebrospinal fluid testing (n = 46, 24 with MS), ⩾6 CVS and ⩾1 PRL diagnostic specificity was 1.00 (95% CI, 0.85, 1.00), similar to that of oligoclonal bands and dissemination in space by magnetic resonance imaging (0.82 [95% CI, 0.60, 0.95]).

DISCUSSION
Integrating CVS and PRL represents potentially advantageous MS diagnostic biomarkers, with increased specificity and without substantial reduction in sensitivity.

Web | PDF | Multiple Sclerosis Journal | Open Access

Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study (2026)

BACKGROUND AND OBJECTIVES
The 2024 McDonald criteria allow diagnosis of multiple sclerosis (MS) in individuals presenting with symptoms not specific for MS or incidental imaging findings suggestive of demyelination when supported by biomarker evidence, reflecting a shift toward diagnostic definitions increasingly grounded in biological mechanisms of disease. The diagnostic yield of these criteria in such populations has not been evaluated in multicenter cohorts. We aimed to determine the proportion of individuals with nonspecific or incidental imaging presentations who meet the 2024 McDonald criteria and describe the contribution of central vein sign and CSF oligoclonal bands (OCBs) to diagnostic classification.

METHODS
This cross-sectional post hoc analysis used data from the Central Vein Sign in Multiple Sclerosis study, a multicenter observational cohort. Adults aged 18–65 years referred for diagnostic evaluation of possible MS were adjudicated by an expert panel. This analysis focused on participants with symptoms not specific for MS or incidental imaging findings suggestive of demyelination. Dissemination in space (DIS) and dissemination in time (DIT) were assessed using 2017 MRI criteria. Fulfillment of the 2024 McDonald criteria at baseline—the primary outcome—was determined using the Select-6 CVS and CSF OCBs. Select-6 assessment was available for all participants, whereas OCB data were available for a subset based on prior clinical evaluation.

RESULTS
Of 420 participants enrolled, 191 (45%) presented with either nonspecific symptoms (n = 166) or incidental imaging findings (n = 25). The mean age was 42 years, and 78% were female. Thirty-six (19%) met the 2024 McDonald criteria at baseline, including 28 (17%) in the nonspecific symptom cohort and 8 (32%) in the incidental imaging cohort. Among 51 participants meeting 2017 DIS, 22 (43%) were Select-6 positive, 17 (33%) had positive OCBs, and 4 (8%) met 2017 DIT. Nonspecific sensory symptoms, visual disturbances, and subacute cognitive decline were most associated with a diagnosis of MS.

DISCUSSION
Application of the 2024 McDonald criteria identified nearly one-fifth of individuals without typical presentations as meeting diagnostic criteria for MS at baseline. Biomarker incorporation—particularly the CVS—accounted for a substantial proportion of diagnostic yield. Interpretation is limited by availability of CSF data and absence of longitudinal follow-up.

Web | PDF | Neurology | Paywall

Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria (2026)

The 2024 revision of the McDonald diagnostic criteria is an important step toward earlier and more inclusive diagnosis of multiple sclerosis. Realizing its full potential will require continued refinement of biomarkers, disease stratification and clinical trial approaches.

Web | PDF | Nature Medicine | Paywall

Application of the 2024 McDonald Criteria (2026)

The evolution of multiple sclerosis (MS) diagnostic criteria over the past 4 decades has shortened the time to diagnosis of MS, enabling earlier institution of immunomodulatory therapy and therefore improved clinical outcomes. In response to a recent expansion of knowledge related to approaches and paraclinical tools that may aid diagnosis of MS and identify causes of MS misdiagnosis, the 2024 McDonald criteria reflect substantive changes and introduce new pathways to MS diagnosis.

These revisions carry potential for both earlier and more accurate diagnosis of MS, yet require expertise for their appropriate application in clinical practice and introduce new challenges for global implementation. These changes include expansion of anatomical locations that represent dissemination in space, new paraclinical findings that can substitute for dissemination in time, inclusion of patients with asymptomatic or nonspecific clinical presentations, and recommendations for diagnostic approaches in specific patient populations.

These changes also incorporate new paraclinical tools for the first time, including MRI central vein sign and paramagnetic rim lesions, CSF kappa free light chains, and optical coherence tomography. The revised criteria have now unified the diagnostic pathway for clinical presentations typical of MS with attack or progressive onset, and established a new pathway for patients without symptoms or with nonspecific clinical presentations accompanied by MRI findings typical of MS. The 2024 revisions continue to rely on recognition of typical clinical and MRI findings of MS, and additionally recommend specific approaches to pediatric patients, patients with vascular comorbidities, and older patients to further reduce the risk of misdiagnosis.

Previous data suggest barriers to implementation, and misunderstanding and misapplication of prior revisions to MS diagnostic criteria that may be associated with misdiagnosis. Implementation of the revised 2024 McDonald criteria globally, particularly in low and low-middle income countries, will require educational outreach, leveraging and maximizing existing resources, and engagement of health care systems to improve access to new technology.

This review contextualizes the implications of key revisions in the 2024 criteria for routine clinical care, while providing accessible guidance for its appropriate application with a lens toward nonspecialist clinicians and trainees globally, to ensure early and accurate MS diagnosis.

Web | PDF | Neurology | Open Access

Paramagnetic rim lesions are highly specific for multiple sclerosis in real-world data (2025)

Paramagnetic rim lesions (PRLs) are an emerging biomarker for multiple sclerosis representing chronic, low-grade intraparenchymal brain inflammation. In addition to associating with greater disease severity, PRLs may be diagnostically supportive. Our aim in this study was to determine PRL specificity and sensitivity for discriminating multiple sclerosis from its diagnostic mimics using real-world clinical diagnostic and imaging data.

This is a retrospective, cross-sectional analysis of a longitudinal cohort of patients with prospectively collected observational data. Patients were included if they underwent clinical evaluation in our academic neuroimmunology centre and had an available MRI scan from the same clinical 3-T magnet that included a T2*-weighted sequence with susceptibility post-processing (Susceptibility Weighted ANgiography protocol, General Electric). Susceptibility imaging-derived filtered phase maps and corresponding T2-fluid attenuated inversion recovery images were manually reviewed to determine PRLs. PRLs were categorized as ‘definite’, ‘probable’ or ‘possible’ based on modified, recent consensus criteria. We hypothesized that PRLs would convey a high specificity to discriminate multiple sclerosis from its MRI mimics.

Five hundred seventy-four patients were evaluated in total: 473 with multiple sclerosis, 53 with non-inflammatory neurological disease and 48 with other inflammatory neurological disease. Identification of ‘definite’ or ‘probable’ PRL provided a specificity of 98% to discriminate multiple sclerosis from non-inflammatory neurological disease and other inflammatory neurological disease; sensitivity was 36%. Interrater agreement was almost perfect for definite/probable identification at a subject level.

PRLs convey high specificity for multiple sclerosis and can aid in the diagnostic evaluation. Modest sensitivity limits their use as single diagnostic indicators. Including lesions with lower confidence (‘possible’) rapidly erodes specificity and should be interpreted with caution given the potential harms associated with misdiagnosis.

Web | PDF | Brain Communications | Open Access
 
It is of interest here though?
Maybe not!

I personally find it of interest. It’s interesting to understand there are stull a lot of grey areas in the diagnosis. From a patient perspective, doctors tend to act with absolute certainty. I’m in Ireland, but got sick in the US so have experienced both sides of the Atlantic healthcare. My dad was told he had MS at 72 by a top Dublin neurologist — despite no real symptoms except transient vision issues but because he had lesions. I was sceptical. I have a friend in the US who had transverse myeletis, was treated with high dose antibiotics, recovered but was still told she now has MS which might pop back at any time.

All of this causes a lot of distress to people, same as the odyssey we all go on with ME. So just trying to understand how all this works and having your explanation of it is helpful to me personally.
 
I find it interesting. Having ME/CFS, a condition which people are both erroneously diagnosed with and diagnosed with other things when they have it, makes people interested in misdiagnosis more generally.

The thread is about "Stories...in the media". We're not aiming high here. Just things that pique people's interest.

It's also interesting in the sense of what may come in the future for ME/CFS. Will diagnosis be relatively straightforward? Or even when/if we have biomarkers and/or imaging to help, will diagnosis still be not-straightforward, as it is in MS? In the future, might post-viral fatigue be considered in relation to ME/CFS as transverse myelitis is to MS? Might we end up with categories a bit similar to Neuromyelitis optica spectrum disorder or Myelin oligodendrocyte glycoprotein antibody disease (share similarities with MS but are not MS) - things that look like ME/CFS but aren't it, that have different courses and respond differently to treatment with various things?

It's also interesting when we read of recoveries, whether from ME/CFS or MS or whatever. Did they instead have one of the conditions that spontaneously resolve, that look a lot like ME/CFS or MS or whatever? That's helpful if you come across an alternative health practitioner claiming they cured themselves of MS. Did they have MS? It's helpful for people to understand more about diagnosis.
 
It’s interesting to understand there are stull a lot of grey areas in the diagnosis.

I agree that is an area of interest. But I think we might get more insight from careful studies of rates of revision of diagnosis from third parties than from news items that suggest that all three people involved - doctor 1, patient and doctor 2 - are either confused about, misconstruing or misreporting aspects of what went on. We don't even know what the diagnosis actually should have been or whether anything has changed. The story does not add up in medical terms. Much as tends to be the case for high profile news articles on people with ME/CFS-like illnesses.
 
I can totally relate to that. The amount of times I heard "Good News, your tests are all negative!"... Many Doctors don't seem to understand that for people with unclear health problems negative tests just mean being left alone with those problems and without therapy options.
Good news, we can rule out cancer!

Well, yeah. Why did we think I might have cancer?????
 
It is of interest here though?
On the stories of misdiagnosis thread? Yes.
She was a well-known actress who left public life due to her health, came back as an MS ambassador and did lots of advocacy, using her profile to raise awareness.
These stories will have most impact in America, where she lives, there may be lots of women in the same position. Their medical system is variable.
I’d rather hear her story of misdiagnosis, than Miranda telling us about her query-Lyme and “ME like illness” which she cured by convincing herself she wasn’t “doing” illness behaviour any more.
 
Back
Top Bottom